Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

Sponsor
Singapore General Hospital
Study ID
NCT03212807
Phase
PHASE2
Status
Withdrawn

Conditions

  • EBV Related Non-Hodgkin's Lymphoma
  • Primary CNS Lymphoma
  • Primary Testicular Lymphoma

Eligibility Criteria

Sex
ALL
Age
21 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Investigational Medicinal Product
  • Lenalidomide — DRUG
    Investigational Medicinal Product

Study Details

PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who fulfill the inclusion / exclusion criteria will be recruited to this trial and treated in this open label, phase 2 trial with the PDL1 inhibitor Durvalumab and Lenalidomide. The combination treatment will be given from the time of recruitment for 6 months when Lenalidomide will be stopped but Durvalumab will continue for a total of 2 years. Response will be assessed by PET / CT scans as per standard lugano criteria.

Key Dates

Start date
Aug 31, 2017
Status verified
Sep 2018
Primary completion
Feb 28, 2021
Completion
Aug 31, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Investigational
    Durvalumab + Lenalidomide

Primary Outcome Measure

Overall Response Rate [ Time Frame: at least 6 months of follow up ]

Related Studies